2.11 Landmark RCTs 一覽 Statin Era 4S (simvastatin, Lancet 1994) — 首部證實 statin 次級預防 WOSCOPS / AFCAPS-TexCAPS — 初級預防 HPS / TNT / PROVE-IT — 強化降 LDL 益處 JUPITER (rosuvastatin, NEJM 2008) — 高 hs-CRP 初級預防 REPRIEVE (pitavastatin, NEJM 2023) — HIV 初級預防 Non-statin LDL Lowering IMPROVE-IT (ezetimibe + simvastatin, NEJM 2015) — doi/10.1056/NEJMoa1410489 FOURIER (evolocumab, NEJM 2017) — doi/10.1056/NEJMoa1615664 ODYSSEY OUTCOMES (alirocumab, NEJM 2018) — doi/10.1056/NEJMoa1801174 ORION-10 / 11 (inclisiran, NEJM 2020) — doi/10.1056/NEJMoa1912387 CLEAR Outcomes (bempedoic acid, NEJM 2023) — doi/10.1056/NEJMoa2215024 CLEAR Outcomes Primary Prevention (bempedoic, JAMA 2023) — JAMA Triglyceride / Omega-3 REDUCE-IT (icosapent ethyl, NEJM 2018) — doi/10.1056/NEJMoa1812792 STRENGTH (omega-3 carboxylic acids, JAMA 2020) — 陰性 PROMINENT (pemafibrate, NEJM 2022) — TG ↓ 但 MACE 無益 JELIS (EPA, Lancet 2007) — 日本 EPA 益處 HoFH / FH-specific ELIPSE-HoFH (evinacumab, NEJM 2020) — doi/10.1056/NEJMoa2004215 TESLA / TAUSSIG (HoFH lomitapide) Lp(a)-targeted OCEAN(a)-DOSE (olpasiran, NEJM 2022) — doi/10.1056/NEJMoa2211023 HORIZON (pelacarsen, phase 3) — 預計 2025–2026 讀出 OCEAN(a)-Outcomes (olpasiran, phase 3) — 進行中 強化降壓 + 強化降脂 TNT, IDEAL, SEARCH, HPS — LDL「lower is better」累積證據 Cholesterol Treatment Trialists (CTT) meta-analysis — 每降 38.7 mg/dL LDL → MACE ↓ ~21%